MENU
TMED
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

TMED stock forecast, quote, news & analysis

The investment seeks long-term capital appreciation... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
TMED
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for TMED with price predictions
Oct 22, 2026

Momentum Indicator for TMED turns positive, indicating new upward trend

TMED saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator turned positive. In 18 of the 18 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for TMED just turned positive on October 15, 2026. Looking at past instances where TMED's MACD turned positive, the stock continued to rise in 15 of 16 cases over the following month. The odds of a continued upward trend are 90%.

Following a +3.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMED advanced for three days, in 69 of 75 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

TMED broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TMED entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Gilead Sciences (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), Intuitive Surgical (NASDAQ:ISRG), CVS HEALTH Corp (NYSE:CVS), McKesson Corp (NYSE:MCK), Elevance Health (NYSE:ELV), Boston Scientific Corp (NYSE:BSX), Humana (NYSE:HUM).

Industry description

The investment seeks long-term capital appreciation. The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of health care companies. The manager defines health care companies as companies engaged in health care innovations, such as developing new and effective therapies; pharmaceuticals; biotechnology; life sciences tools and services; managed health care; and/or health care equipment, supplies, providers, services, distributors, and facilities. The fund is non-diversified.

Market Cap

The average market capitalization across the T. Rowe Price Health Care ETF (TMED) ETF is 64.44B. The market cap for tickers in the group ranges from 36.91M to 1.13T. LLY holds the highest valuation in this group at 1.13T. The lowest valued company is EYPT at 36.91M.

High and low price notable news

The average weekly price growth across all stocks in the T. Rowe Price Health Care ETF (TMED) ETF was 2%. For the same ETF, the average monthly price growth was -1%, and the average quarterly price growth was 16%. IRON experienced the highest price growth at 32%, while EYPT experienced the biggest fall at -86%.

Volume

The average weekly volume growth across all stocks in the T. Rowe Price Health Care ETF (TMED) ETF was 13%. For the same stocks of the ETF, the average monthly volume growth was 14% and the average quarterly volume growth was 3%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 47
Price Growth Rating: 49
SMR Rating: 77
Profit Risk Rating: 81
Seasonality Score: 20 (-100 ... +100)
Momentum Indicator for TMED turns positive, indicating new upward trend